Wise Equity agrees to acquire E-Pharma Trento to expand Italian pharmaceutical CDMO platform

The proposed acquisition gives Wise Equity control of a specialist oral solid-dose manufacturer with established capabilities in effervescent, soluble, orally disintegrating and sublingual formulations.

Italian private equity firm Wise Equity has agreed to acquire 100% of E-Pharma Trento, a contract development and manufacturing organisation specialising in oral solid dosage forms, from healthcare distribution group Unifarm.

The transaction gives Wise Equity a pharmaceutical CDMO with development, manufacturing and licensing capabilities and approximately €55 million in revenue, providing a platform for further growth in Italy and international markets.

Field	Content
Alert Type	Deal
Companies	Wise Equity; E-Pharma Trento; Unifarm
Deal Type	Acquisition
Asset or Company	100% of E-Pharma Trento
Therapy Area(s)	Multiple
Technology or Modality	Pharmaceutical CDMO specialising in oral solid dosage forms, including effervescent, soluble, orally disintegrating and sublingual formulations
Deal Value	Financial terms have not been disclosed.
Geography	Italy; international markets
What Happened	Wise Equity has signed an agreement to acquire 100% of E-Pharma Trento from Unifarm through its Wisequity VII fund. E-Pharma is an Italian CDMO specialising in oral solid dosage forms and provides services spanning product development, commercial manufacturing and out-licensing of registration dossiers. The transaction has been announced but remains subject to completion; financial terms have not been disclosed. E-Pharma currently identifies Unifarm as its sole shareholder. (epharmatrento.it)
Why It Matters	The acquisition gives Wise Equity an established pharmaceutical manufacturing platform with specialist formulation technologies and both domestic and international business. E-Pharma reports approximately €55 million in revenue, with pharmaceuticals accounting for 65% of its business and international markets representing 35%, providing a base from which the new owner could pursue further CDMO growth. (e-pharma.com)
Supporting Context	Founded in 1993, E-Pharma operates two plants in Trento and reports 276 employees, production of more than 611 million dosage units and approximately 240 manufactured SKUs. Its capabilities include contract development, manufacturing and regulatory support, alongside patented technologies covering areas including orally disintegrating formulations and packaging. (e-pharma.com)
Strategic Rationale	Wise Equity gains a specialised pharmaceutical CDMO with established manufacturing infrastructure, proprietary formulation technologies and international customers. The acquisition provides a platform from which the investor could support organic expansion or additional acquisitions, although specific future investment plans have not been disclosed.
Key Takeaway	The acquisition gives Wise Equity control of a €55 million-revenue specialist CDMO with established oral solid-dose development and manufacturing capabilities.
What to Watch	Completion of the transaction and Wise Equity's subsequent plans for investment, capacity expansion, international growth or further CDMO acquisitions around E-Pharma.
Primary Source	https://www.pehub.com/wise-equity-inks-agreement-to-acquire-e-pharma-trento/
Relevant Date	10 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com